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QUANTIFYING THE BENEFITS OF THE EXPANDED FOOD AND NUTRITION 




The Expanded Food and Nutrition Education Program (EFNEP) is among the major 
nutrition education programs funded by the United States Department of Agriculture 
(USDA) with the aim of reducing food insecurity among low-income families. The 
program reaches about 70,000 adults and youth of low-income families in the US, District 
of Columbia, and six U.S. territories. 
Prior studies have used self-reported data, which possesses measurement errors, to estimate 
the benefits of the program. This can lead to underestimation or overestimation of results. 
To address this limitation, I use clinically measured objective biomarkers, such as body 
mass index (BMI), blood sugar level (HbA1C) and blood pressure to estimate the benefits 
of EFNEP and compare it to the program costs. Results show that EFNEP benefits 
outweigh program costs. However, the use of self-report data underestimates the benefits 








The Expanded Food and Nutrition Education Program (EFNEP) is one of the 
leading nutrition education programs aimed at reducing nutrition insecurity of low-income 
families and youth in the United States. Established in 1969 by the US government and 
managed by the USDA NIFA, EFNEP is among the earliest nutrition education programs 
and remains at the forefront of food and nutrition educational efforts (USDA, 2020). The 
program’s main aim is to reduce nutrition insecurity among U.S low-income families and 
youth. EFNEP currently operates through the 76 Land-Grant Universities (LGUs) in every 
state, the District of Columbia, and six U.S. territories – American Samoa, Guam, 
Micronesia, Northern Marianas, Puerto Rico, and the Virgin Islands.  
As a community-based nutrition education program, the goal of EFNEP is to 
address the health issues of the community as well as to improve the nutritional well-being 
of low-income households. EFNEP focuses on four main education areas: improving the 
quality of diet and physical activity of participants, proper food resource management, food 
safety and food security (USDA, 2020). These goals are accomplished through the 
participants’ increased knowledge of the essentials of nutrition, as well as from increased 
skills in food selection, purchasing, preparation, production, storage, safety, and sanitation. 
The program also seeks to enhance the ability of participants to manage resources relating 
to food. The program receives about $70 million in federal funding each year and reaches 
approximately 650,000 adults and youth in both rural and urban areas (USDA, 2020). 





(2011), conclude that EFNEP is an effective use of tax dollars i.e. the benefit of EFNEP in 
terms of avoiding or delaying specific chronic diseases, improvements in participants’ food 
expenditures, and changes in nutritional behaviors exceed program costs. 
 
1.2 Problem Statement 
Over the years, several studies have evaluated the economic efficiency of EFNEP 
(Lambur et al., 1998; Burney et al., 2002; and Koszewski et al., 2011).  Limitations of the 
existing literature, particularly in estimating the direct benefits of EFNEP, motivate this 
study. These limitations include the use of self-reported behavioral data, which are dietary 
recalls from participants of EFNEP, to determine those who have benefited from the 
program. Dietary recalls, which are collected through interviews before their first lesson 
and at the last lesson are used to determine those who benefit from the program by 
following the behaviors taught in the program. Benefits are measured as the number of 
people who have improved their nutrition and health behaviors after graduating from the 
program, and hence able to avoid or delay the onset of specific chronic diseases. There are 
obvious limitations to self-reporting in that some people may not remember past diets and 
physical activity correctly, or they may have difficulty quantifying them accurately (Hagen, 
2012). The use of self-reported data and the dietary measurement error it poses can cause 
underestimation or overestimation of results (Rosenman et al., 2011). These limitations 
likely biased the results of prior EFNEP impact and cost-benefit analyses.  
Considering the large amount of federal funding allocated to EFNEP (e.g. 
$69,400,680 for 2020) (NIFA,2020), a thorough cost-benefit analysis is needed to advance 
the literature by developing a cost-benefit analysis model that provides more accurate 





with the use of self-reported behavioral data, I make use of objective, quantitative 
biological markers (biomarkers) reflective of nutritional intake and indicative of chronic 
disease risk (Combs et al., 2013). Biomarkers provide unbiased measurements and are 
therefore useful to validate self-report instruments (Hagen, 2012). Examples of biomarkers 
include body mass index (BMI), blood pressure (BP) and blood sugar level (HbA1C). This 
study will provide other nutrition education programs with a more accurate, easy-to-use 
procedure for conducting an economic analysis and give useful information to the 
administrators of EFNEP and similar nutrition education programs.  
 
1.3 Objectives 
The main objective of this study is to develop and apply a cost-benefit analysis 
methodology that provides more accurate estimates of the net benefit of EFNEP by using 
objective biomarker data. The specific objectives are to (1) quantify EFNEP benefits using 









2.0 LITERATURE REVIEW 
2.1 Cost-Benefit Analysis 
Cost-benefit analysis (CBA), also referred to as benefit-costs analysis, is a 
systematic method to ascertain the value (benefits) of programs or projects against their 
costs where both are expressed in monetary terms. Results of CBA are usually expressed 
as discounted net benefits (program benefits minus program costs), as a rate of return, or 
as a ratio of benefits to costs, (Boardman et al. 2017). CBA provides a framework for 
measuring the efficiency of programs and projects. It can be thought of as a situation in 
which resources, such as land, labor, and capital, are employed in their highest-valued uses. 
(Boardman et al. 2017).  
Such a quantitative comparison of program’s benefits to its costs has been widely 
applied in the evaluation of health programs including EFNEP within the United States. 
Rajgopal, Ruby, Lambur, and Lewis (2002) define the benefits of a program as the 
outcomes or consequences that participants or non-participants derive from the program. 
The primary positive outcome that participants and others involved in the program derive 
directly is referred to as the direct benefit of the program. The secondary outcomes that 
program participants and non-participants or society derive indirectly are referred to as its 
indirect benefits.  
Costs can also be categorized as direct or indirect costs. Budgeted resources are 
used directly in the administration of the program while some resources are not budgeted 
for but are necessary for operating or running the program. These are referred to as direct 





individuals for direct involvement in the program. For example, indirect costs include the 
lost work hours due to participation in the program (Lambur, Cox, & Ellerbrock, 1998).  
2.2 Economic Evaluation of EFNEP 
Among the earliest economic evaluations of EFNEP is that of Virginia which 
evaluated the cost-benefit of Virginia EFNEP using the CBA methodology (Lambur et al. 
1998). Direct benefits were measured as benefits from chronic diseases and conditions that 
are diet-related and that would have been delayed or avoided if participants adopted the 
behaviors that were taught and measured by EFNEP. The measurement of changes in 
behavior was captured from 24-hour dietary recalls reported by participants before and at 
the exit of the program. The Virginia methodology calculates direct benefits as the present 
value of the medical costs ($ dollars) saved per disease/condition multiplied by the number 
of EFNEP graduates who practiced food behaviors associated with avoiding or delaying 
the onset of the specific disease/condition (Lambur et al. 1998). Indirect benefits were 
measured as benefits that accrued to EFNEP participants due to increased work 
productivity. When a person becomes sick or dies, his or her earnings or productivity are 
threatened since he or she cannot work anymore. It is beneficial to avoid or delay the onset 
of a disease/condition because it has the potential of increasing an individual’s 
productivity/earnings significantly. Also, the possibility of avoiding or delaying illness 
benefits society indirectly because it increases people’s ability to work. Costs used in the 
Virginia methodology were direct administrative costs of the program (Radhika et al. 
2002).  
Lambur et al. (1998) and Radhika et al. (2002) categorized the disease/conditions 





are associated with nutritional behaviors that are expected to be affected positively by 
appropriate diet behaviors. These are heart disease, colorectal cancer, hypertension, and 
stroke. Type B disease/conditions are non-life-threatening diseases that are also associated 
with nutritional behaviors which are expected to be affected positively by appropriate diet 
behaviors. These are obesity, type 2 diabetes, osteoporosis, foodborne illness, and 
commonly occurring infant diseases. Type C disease/conditions are those whose cost of 
treatment is incurred only once such as low birth weight (LBW) in infants. The direct 
benefit of type C disease is based on the present value of avoiding the costs of treating an 
infant with low birthweight.  
After calculating program benefits and costs, Lambur et al. (1998) used three 
analytical measures of benefits, namely benefit-cost ratio (BCR), internal rate of return 
(IRR), and net present value (NPV) to measure the efficiency of Virginia EFNEP. They 
used the 1996 Virginia adult EFNEP self-reported data from the EFNEP Evaluation 
Reporting System which included pre and post self-reported data on program participants’ 
food-related behaviors. The authors concluded that Virginia EFNEP generates a significant 
return on investment with a $10.64/$1.00 benefit to cost ratio. Addressing the uncertainty 
of whether the results were due to assumptions in their analysis, such as the unavailability 
of estimates of incidence rates for some of the disease conditions for low-income 
households, they conducted several sensitivity analyses. The result of the sensitivity 
analysis was a benefit to cost ratios ranging between $2.66/$1.00 and 17.04/$1.00.  
Other studies have looked at the economic evaluation of the EFNEP program in 





(Lambur et al. 1998; Radhika et al. 2002). These studies have been summarized in Table 
1. 
2.3 Behavioral Changes of EFNEP Participants 
 
 Burney et al., 2002 analyze whether the benefits of participating in 
EFNEP exceed its cost and if these positive behaviors are maintained over a long period. 
Using an experimental design in the cost-benefit analysis methodology, a sample size of 
384 participants was randomly assigned to one of three different groups to determine 
improvements in participants’ food expenditures. Group A are those who received nutrition 
education from EFNEP and collected cash receipts for their food purchases; Group B are 
those whose food expenditures were estimated from recall; and Group C, the control group, 
are those who had qualified for enrollment in the program but had to start their lessons after 
groups A and B had graduated from the program. Cash receipts to determine food 
expenditures were used to differentiate Group A from Groups B and C. Using the Analysis 
of Variance technique, comparing the combined experimental group (A and B) with the 
control group, data gathered from food and nutrition intake between entry and exit of the 
program showed positive average changes in food and nutrition intake. Statistically, 
changes in food and nutrition intake by the experimental group were significantly higher 
than those of the control group after participating in EFNEP.  Also, there were significantly 
higher mean scores of food resources management practices for the experimental group 
than the control group. Pairwise comparisons between groups were made and the results 
showed that EFNEP participants had the most improvement in their food expenditures and 





graduation. To compare the benefits, which is the amount of money saved on food 
expenditures to the costs, the net present value (NPV) ranged from $147 to $696. 
Almost all the studies on the economic evaluation of EFNEP have demonstrated 
that the benefits of EFNEP exceed its cost (Amstutz and Dixon, 1969; Arnold and Sober, 
2000; Greer and Poling, 2001). But another question of interest and importance is how long 
will such positive nutritional behaviors and benefits be sustained? To answer this question, 
Koszewski et al. (2011) determined if graduates from either SNAP-Ed or EFNEP in 
Nebraska showed changes in their behavior 6 months after completing the program. Data 
for the analysis was gathered from EFNEP’s Behavior Checklist Survey and analyzed 
using chi-square analysis to determine the effectiveness of SNAP-Ed/EFNEP nutrition 
education six months after graduation. The authors found that 25% (n=1,100) of the 
graduates from the two programs improved and maintained their behaviors within the entry 
and exit of the program, as well as 6 months later. This result was emphasized by Wardlaw 
and Baker, (2012) who also conducted a long-term evaluation of EFNEP and SNAP-Ed 
using checklists and semi-structured interviews to identify the changes in behavior, food, 
and nutrition behaviors as well as other life changes attributed to their involvement in the 
program over time. The study sample were previous graduates who were enrolled within 
one to four years.  The results of their study indicate that following EFNEP participation, 
graduates maintained positive food- and nutrition-related behaviors for approximately one 
to four years within the period which they were enrolled and they performed these 
behaviors more often than non-participants.  
The research presented in this subsection indicates positive findings on the 





there are several limitations associated with the approaches used in these studies such as 
their use of self-reported data on dietary intake and behavior changes. This limitation 
creates the potential for self-report bias (Rosenman et. al, 2011). Participants may make 
more acceptable answers or recall rather than being truthful or may not be able to remember 
their food behaviors accurately.  
2.4 Self-Report Data and Biomarkers 
One challenge in nutrition and health care evaluation is the use of self-reported data 
and the measurement error it poses which can cause underestimation or overestimation of 
results. Few studies have evaluated self-reported dietary intake data against objective data. 
Park et al. (2018) estimated the prevalence of under- and overreporting of dietary intake 
by comparing self-reported dietary intakes which were gathered from the automated Self-
Administered 24-hr recall (ASA24s), 4-d food records (4DFRs), and food-frequency 
questionnaires (FFQs) against recovery biomarkers. Over a study period of 12 months, 530 
men and 545 women, aged 50–74 years were made to complete automated Self-
Administered 24-h recall (ASA24s), 2 unweighted 4-d food records (4DFRs), 2 FFQs, two 
24-h urine collections (biomarkers for protein, potassium, and sodium intakes), and 1 
administration of doubly labeled water (a biomarker for energy intake). When absolute 
intakes of some nutrients were assessed by all self-reported instruments, they were found 
to be systematically lower than the absolute intakes of the same nutrients accessed from 
recovery biomarkers, though there was underreporting of energy which was greater 
compared to the other nutrients. Nutrients accessed were energy, protein, potassium, and 
sodium. Comparing estimates of dietary intake from self-reported data with the biomarkers, 





29–34% on FFQs. FFQs had the most underreporting compared to ASA24s and 4DFRs 
and among obese individuals. Mean protein and sodium densities on ASA24s, 4DFRs, and 
FFQs were similar to biomarker values, but potassium density on FFQs was 26–40% 
higher, which led to a significant increase in the prevalence of overreporting compared 





Table 1: Economic Evaluations of the Expanded Food and Nutrition Education Program. 
Citation Objectives Methodology Results 
Dollahite, Jamie, Donald 
Kenkel, and C. Scott 
Thompson. "An economic 
evaluation of the 
expanded food and 
nutrition education 
program." Journal of 
nutrition education and 
behavior 40, no. 3 (2008): 
134-143. 
Use economic methodology to 
evaluate New York State EFNEP  
Design: Estimating potential 




effectiveness are from 
behavior change and QALY 
weights. 
 
Subjects: 5730 low-income 
participants. 
 
Setting: 35 counties of New 
York State 
 
Benefit-to-cost ratio of $9.58:$1.00 
(sensitivity $1.44-$41.92:$1:00); 
 
Narrow governmental benefit-to-cost 




Hradek, Christine, Helen 
H. Jensen, Nicole 
Schimerowski Miller, and 
Miyoung Oh. "Evaluation 
of the Cost and 
Effectiveness of Direct 
Nutrition Education to 
Low-Income Audiences in 
Iowa: EFNEP and SNAP-




Evaluate the costs and benefits of 
EFNEP and SNAP-Ed programs 
as well as update a study 
conducted in Iowa from 1998 to 
2000. 
Design: Analyze outcomes 
and costs based on updated 
data collected from the Iowa 




Subjects: 947 graduate 
participants. 
 
Setting: Iowa State. 
Benefit-to-cost ratio of $2.48/$1.00 
 
Less restrictive measures of benefits 
lead to 
benefit-to-cost ratios between 





Joy, A., Vijay Pradhan, 
and George Goldman. 
"Cost-benefit analysis 
conducted for nutrition 
education in 
California." California 
Agriculture 60, no. 4 
(2006): 185-191. 
Justify and determine 
expenditures and ensure 
continued funding by 
documenting the cost-
effectiveness of nutrition 
education programs  





Settings: California State 
Benefit-cost ratio of 14.67/1.00. 
(Sensitivity 3.67 to 1.00, to 8.34 to 
1.00) 
Schuster, Ellen, Zelda L. 
Zimmerman, Molly 
Engle, Janice Smiley, 
Ellen Syversen, and Jill 
Murray. "Investing in 
Oregon's Expanded Food 
and Nutrition Education 
Program (EFNEP): 
documenting costs and 
benefits." Journal of 
nutrition education and 
behavior 35, no. 4 (2003): 
200-206. 
To estimate a cost-benefit ratio 
for Oregon’s EFNEP by applying 
the standard CBA model from 
Virginia study. 
Design: Standard Virginia 
methodology. 
 
Subjects/Settings: 368 adult 
graduates of Oregon State 
University’s Extension 
Service EFNEP during the 
1999-2000 program year. 





Rosenman et al. (2011), further demonstrate how to identify self-reported data bias 
in response and its covariates by examining how participant demographics affect response 
bias before and after program participation. The stochastic frontier model (SFE) by Aigner 
et al. (1977) and Meeusen and van den Broeck (1977) was the approach of measuring 
response bias and its changes between two time periods. They conclude that the magnitude 
of bias and its changes across time are affected by gender and race/ethnicity which is lower 
at post-test than at the pre-test. 
To address the problem of dietary measurement bias error, efforts have been made 
to use biological markers (biomarkers) of nutritional intake (Freedman et al., 2010). 
Examples of such biomarkers include weight, body mass index (BMI), blood pressure (BP) 
and blood sugar level (A1C). Information on physiological or biological responses to 
dietary behavior can provide information on interindividual differences in response to diet 
and nutrition revealed by such measurements and be useful to monitor responses to 
interventions (Hagen, 2012). Biomarkers provide almost unbiased measurements and are 







3.0 DATA AND METHODOLOGY 
3.1 Participants 
EFNEP participants are primarily families with income below the poverty line (USDA, 
n.d.). Approximately 70% of EFNEP participants are indicated to be of minority status 
(USDA n.d.). The program focuses on minority and low-income groups given their 
disproportionate risk for chronic diseases and poor health (USDA n.d.).  This study’s 
population was composed of 1,507 graduates of EFNEP in both states in 2016-2017, of 
which 725 were in Washington and 782 were in Colorado. EFNEP graduates are 
participants who completed all their lessons as well as both the entry and exit interviews 
(Wessman et.al, 2001). The sample for the study is 129 EFNEP graduates of average age 
of 37 years, all of whom are females, with complete data for dietary recalls, biometric 
measures and food practice scores. EFNEP graduates are defined as program participants 
who completed all their lessons as well as both the entry and exit interviews (Wessman 
et.al, 2001). Participants were recruited during the first EFNEP class, during which they 
agreed to allow collection of their biometric measures.  
For each individual, the biometric measures collected are, height, weight, body 
mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), blood 
sugar level (HbA1C), and pulse rate. These measures were collected with clinical 
diagnostic instruments and taken at four different time points: pre (at the first lesson), post 
(at the final lesson), and 6 and 12 months after the lesson series. At each time point, the 





given cash incentives of $30 (pre), $30 (post), $50 (6 months post), and $50 (12 months 
post). (RNECE final report, 2019). 
Table 2: Demographic and biometric data from pretest(n=129)  
Variable Mean (sd)  
Age (Years) 37.4 (10.7) 
Colorado State  
Washington State  
Height (cm) 159.0(7.5) 
Weight (kg) 80.8(20.9) 
BMI (kg/m2) 31.9(7.6) 
Systolic blood pressure (mmHg) 109.0(12.4) 
Diastolic blood pressure (mmHg) 75.6(8.6) 
Hemoglobin A1c 5.6(0.9) 
Pulse Rate 77.5(24.5) 
Number of complete observations  





Figure 1 summarizes the pre-EFNEP biometric indicators for the sample of 129 EFNEP 
participants. The majority of the sample participants were between the ages of 25 and 40 
years. At the first lesson, most of the participants weighed between 60kg and 120kg and 
were between 155cm and 175cm tall. Some participants had weight above 120kg with two 
out of the five outliers having height above 175cm.  
Body Mass Index (BMI) was centered between 20 kg/m2 and 50 kg/m2 with the 
Hemoglobin A1C Test (HbA1C)  centering between 4mmol/L and 7mmol/L. Normal BMI 
range is between 18.5 to 24.9 kg/m2. BMI range greater than 29.9 are considered obese 
(Center for Disease Control, 2020). Normal blood sugar levels (HbA1C) ranges below 
5.7mmol/L.  HbA1C levels greater than 6.5mmol/L are considered diabetic. Participants  
Figure 1: Pre-EFNEP demographic and biometric data distribution 
with higher systolic blood pressure (SBP) also had high diastolic blood pressure (DBP). 
Most of the participants who had SBP between 80mmHg and 130mmHg also had DBP 
between 60mmHg and 90mmHg. Normal ranges of SBP and DBP are less than 120mm Hg 





The main cost-benefit analysis will be done with the entire data excluding participants with 
missing values. 
3.2 Data 
Both primary and secondary data play an important role in quantifying the 
economic benefits of EFNEP. To calculate the direct and indirect benefits of EFNEP, 
primary and secondary data were obtained from four sources. Biomarkers were collected 
in 2017 and 2018 as part of the long-term follow-up evaluation of EFNEP by the Regional 
Nutrition Education and Obesity prevention Centers of Excellence (RNECE). Identical 
models of the clinical equipment were used at each time point by trained professionals to 
collect the biometric measurements including scales, stadiometers, blood pressure 
monitors, and HbA1c test kits.   
The goal of the evaluation was to determine if EFNEP impacted participants’ 
biomarkers (BMI, BP, HbA1c) and if participants of EFNEP could be retained for one year 
(RNECE final report, 2019). Demographic characteristics, food and physical activity 
questionnaires and 24-hour dietary recalls are administered at entry and at exit to measure 
behavior change. This was collected through EFNEP's Web-Based Nutrition Education 
Evaluation and Reporting System (WebNEERS). Food Practice Checklist (FPC) questions 
were answered by the participants to measure specific food consumption and handling 
behaviors on a scale of 1-5. 
 In addition to biomarker and WebNEERS data, estimates from the literature 
(Hradek et. al., 2015) were used to calculate program direct and indirect benefits. These 
estimates include average age of onset and years of survival of the diseases, number of 
years diseases are delayed as a result of participation in EFNEP, per patient medical costs 





workdays, incidence rate of the disease in the low-income population, incidence rate of the 
disease related to diet, incidence rate of disease related to biomarkers and minimum wage 
rate. Annual costs of lost workdays were obtained by multiplying the average number of 
annual lost workdays, eight hours of daily work hours and the 2020 federal minimum 







































Type A Diseases 
Colorectal 
Cancer 37 50 5 5 78 $34,793 65 50 $2,900.00  
Heart disease 37 55 5 5 78 $14,830 65 59 $3,422.00  
Stroke 37 45 10 5 78 $22,984 65 65 $3,770.00  
Hypertension 37 41 20 5 78 $805 65 40 $2,320.00  
Type B Diseases 
Osteoporosis 37 50     78 $10,669 65 7 $406.00  
Type 2 
Diabetes 37 54     78 $8,670 65 11 $638.00  
Obesity 37 40     78 $2,046 65 3.72 $215.76  
Foodborne 
Illness 37 24     78 $1,811 65 1.5 $87.00  
Infant 
Diseases 37 0     78 $2,539 65     
Type C Diseases 
Low 
Birthweight 37 0     78 $21,799 65   






Data on direct costs (Table 4) are also utilized in this study. Direct costs associated 
with EFNEP were annual direct costs of adult EFNEP (2018 Dollars) obtained from 
collaborators on the pilot project. The direct costs consisted of the value of resources, 
including direct payments of real and in-kind dollars, used in program administration and 
implementation. They included salaries and benefits; facilities (office space, IT support 
and utilities); equipment, supplies and training; staff travel; and marginal excess burden 
(17%). 
Table 4: Summary of Annual Direct Costs (2018 Dollars) - FTE % Approach  
Category Cost 
Salaries and Benefits $1,221,053.80 
Office Space $124,204.77 
Utilities $13,217.29 
Equipment, Supplies and Training $155,195.62 
Staff Travel $43709.56 
Marginal Excess Burden (17%) $264754.78 
Total Direct Cost $1822,135.82 
Source: (Administrative costs assembled from EFNEP Washington and Colorado 
Extension) 
 
3.3 The Cost-Benefit Analysis Methodology.  
Cost-benefit analysis (CBA) is commonly used to inform society which project or 
program to choose from among a number of similar programs. An accurate CBA thus 
requires a precise and unbiased definition or identification of benefits and costs that are 
generated from the program (Torrance, G.W, 2006). To decide on the desirability of a 
project, all positive and negative aspects of the project should be expressed in terms of a 
common unit (Watkins and Valley, 2006). The most convenient and most used common 





terms of their equivalent money value of a particular time. The CBA methodology is 
applicable for this study as it analyzes a single program to determine whether its benefits 
outweigh its cost. The program has economic value if it contributes positively to human 
well-being (Frew, E., 2010). The ultimate role of CBA is to aid in allocating scarce 
resources.  
Results of CBA are usually represented as (1) the discounted net benefit, which is 
the difference between program benefits and costs, (2) a ratio of benefits to costs, or (3) a 
rate of return (Net Present Value (NPV)/Internal Rate of Return (IRR)) (Boardman et al. 
2017).  Discounting is a way to compare benefits and costs that occur in different time 
periods by expressing their values in present terms since a dollar available five years from 
now is not as good as a dollar available now. That dollar can be invested and earn interest 
in the next 5 years. For example, if r is the interest rate, then investing $1 now will grow 
to be of 1(1 +  𝑟)𝑡 in the next t years. Therefore, the amount of money needed to be 
deposited to today so that it will grow to be $1 in the next t years is 1(1 +  𝑟)−𝑡. 1(1 +  𝑟)−𝑡 
is referred to as the present value of $1 which will be available in the future. (1 +  𝑟)𝑡 is 
called the discount factor. When applied properly, discounting can inform us about how 
much a future benefit or cost of a project or program is worth today (Neubauer et al., 2010). 
Thus, when the dollar value of the benefits or costs of a project is multiplied by the 
discounted value of $1 at that future time, the result referred to as the discounted present 
value (Watkins and Valley, 2006).  CBA provides a framework for measuring the 
efficiency of programs and projects and it can be thought of as a method whereby resources 
are valued in their highest-valued uses. (Boardman et al. 2017). Such a quantitative 





of health programs within the United States (Schuster et al, 2006, Hradek et al., 2017).  The 
cost-benefit ratio is used to ascertain the value of a program by determining whether its 
benefits outweigh its costs within a specific period. The ratio gives the value of the 
discounted benefits obtained per the costs of the program and is defined as follows: 
 
𝐶𝑜𝑠𝑡 − 𝐵𝑒𝑛𝑓𝑖𝑡 𝑅𝑎𝑡𝑖𝑜(𝐵𝐶𝑅) =
𝑃𝑟𝑒𝑠𝑒𝑛𝑡 𝑉𝑎𝑙𝑢𝑒 𝑜𝑓 𝑇𝑜𝑡𝑎𝑙 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑠














where r is the discount rate which captures the level of future uncertainty and n is the 
number of years in the future for discounting. 
A potentially worthwhile project is one which has its discounted present value of 
the benefits exceeding the discounted present value of the costs. Equivalently, the ratio of 
the present value of the benefits to the present value of the costs (cost-benefit ratio) must 
be greater than one. A cost-benefit ratio of less than one means that discounted present 
value of the costs exceeds the discounted present value of the benefits. A benefit-cost ratio 
that is equal to 1 means that there is a break-even situation where the discounted present 
value of the benefits of the program equals its discounted present value of costs. When 








3.4 Monetizing Benefits of EFNEP 
Estimated medical costs avoided or delayed for each disease/condition represented 
the direct benefits of EFNEP. The assumption is that participants practicing Optimal 
Nutritional Behaviors (ONB) and those with biomarker improvement will save these 
medical costs by avoiding or delaying the diseases. Benefits such as reduced food costs, 
food production and preservation, better use of nutritional food related resources and job 
readiness and performance would not be included in the benefit calculations because these 
data are not consistently or routinely collected across states in EFNEP and cannot be easily 
monetized (Rajgopal et al., 2002). 
Medical costs used were 2017 present value medical costs of diseases obtained 
from existing literature (Hradek et al., 2017). The future benefits for each disease which 
were the costs avoided for some specific time periods were discounted to 2020 dollars at a 
discount rate of 5% which is the rate used for most cost benefit analyses (CBAs) in 
healthcare studies (Rajgopal et al., 2002). Indirect benefits that accrue to EFNEP 
participants are the lost earnings of wages from lost productivity. This indirect benefit 
calculation assumes that the individual loses personal wages from lost workdays when he 
or she becomes ill from any of these chronic diseases. The 2020 federal minimum wage 
for employees of $7.25 per hour were used in calculating the lost earnings from lost 
productivity. Chronic diseases and conditions are categorized into three types: Type A, 






The monetized benefit of avoiding or delaying a disease/condition is the sum of the 
present value of direct benefits (medical costs avoided or delayed) and the present value of 
indirect benefit (lost earnings of wages from lost productivity forgone), as follows. 
 
 
Estimated PV Benefits = PV of direct benefit + PV of indirect benefit 














3.5 Type A Disease Benefits 
Type A consists of life-threatening diseases, which are normally incurable, can 
considerably reduce a person's life expectancy and are associated with nutritional 
behaviors that are expected to be affected positively by appropriate diet behaviors. These 
are heart disease, colorectal cancer, hypertension, and stroke. The estimated present value 
of total benefit of type A disease consist of direct and indirect benefit of delaying the onset 
of the disease: 
 
Est PV benefits of  delaying Type A disease = 
= PV of  Type A direct benefit + PV of Type A indirect benefit 
= ∑ (













The direct benefits of type A diseases are the present value of medical costs avoided as a 
result of delaying the onset of the diseases as a result of participation in EFNEP. For 
example, if the average age of onset of a type A disease is at age 50, and EFNEP can delay 
the onset for 5 years to age 55, then the estimated present value medical cost avoided for 
the 5 years of delay (from age 50 to 54) becomes the benefit of delaying the disease. For 





survival. The direct benefit of type A diseases is calculated as the difference between the 
sum of the present value of treatment costs from average age of onset to average age of 
death and the sum of the present value of the treatment costs from the delayed age of onset 
to the delayed age of death. The present value of all benefits is discounted to 2020 dollars 
to determine how much future benefit is worth today.  
 
𝑃𝑉 𝑜𝑓 𝑇𝑦𝑝𝑒 𝐴 𝑑𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 =  
= ∑ (















𝑃𝑉 𝑜𝑓 𝑀𝑒𝑑𝑖𝑐𝑎𝑙 𝑐𝑜𝑠𝑡𝑠𝑓𝑟𝑜𝑚 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡 = 
= ∑ (









𝑃𝑉 𝑜𝑓 𝑀𝑒𝑑𝑖𝑐𝑎𝑙 𝑐𝑜𝑠𝑡𝑠𝑓𝑟𝑜𝑚 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡 = 
= ∑ (
𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×








Table 5: Type A disease Direct Benefit Illustration: 
Present value of Stroke treatment 
cost if incurred at age of onset till 
death 
 Present value of stroke 
treatment cost if delayed for 5 
years 
Age year PV Age year PV 
37-44 8 $0.00 37-49 13 $0.00 
45 9 $14,815.42 50 14 $11,608.27 
46 10 $14,109.93 51 15 $11,055.50 
47 11 $13,438.03 52 16 $10,529.04 
48 12 $12,798.12 53 17 $10,027.66 
49 13 $12,188.69 54 18 $9,550.15 
50 14 $11,608.27 55 19 $9,095.38 





52 16 $10,529.04 57 21 $8,249.78 
53 17 $10,027.66 58 22 $7,856.94 
54 18 $9,550.15 59 23 $7,482.80 
Total   $120,120.81 Total $94,117.80 
PV of Direct Benefit of delaying Stroke = $120,120.81 - $94,117.80 = $26,003.01 
 
Type A disease indirect benefits are the loss of productivity avoided due to the 
delay of the onset of the diseases. The loss of productivity prevents the individual from 
earning wages. Therefore, the benefits from avoiding the loss of productivity are the wages 
that would have been forgone. The indirect benefit of type A diseases is the difference 
between the sum of the present values of lost wages from the average age of onset to 
average age of death and the sum of the present value of lost wages from the delayed age 
of onset to the delayed age of death – discounted to 2020 dollars. 
 
𝑃𝑉 𝑜𝑓 𝑇𝑦𝑝𝑒 𝐴 𝐷𝑖𝑠𝑒𝑎𝑠𝑒 𝐼𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝐵𝐸𝑛𝑒𝑓𝑖𝑡 =  
=  ∑ (
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𝑃𝑉 𝑜𝑓 𝐿𝑜𝑠𝑡 𝑊𝑎𝑔𝑒𝑠𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡 = 
=  ∑ (
𝐴𝑛𝑛𝑢𝑎𝑙 𝑙𝑜𝑠𝑡 𝑜𝑓 𝑤𝑎𝑔𝑒𝑠 ×









𝑃𝑉 𝑜𝑓 𝐿𝑜𝑠𝑡 𝑊𝑎𝑔𝑒𝑠𝑓𝑟𝑜𝑚 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑎𝑔𝑒 𝑜𝑓 𝑜𝑛𝑠𝑒𝑡 = 
=  ∑ (
𝐴𝑛𝑛𝑢𝑎𝑙 𝑙𝑜𝑠𝑡 𝑜𝑓 𝑤𝑎𝑔𝑒𝑠 ×













Table 6: Type A Disease Indirect Benefit Illustration: 
 
3.6 Type B Diseases Benefits 
Type B disease and conditions are non-life-threatening diseases, which are diseases 
that can be treated and are also associated with nutritional behaviors that are affected 
positively by appropriate diet behaviors. These are obesity, type 2 diabetes, osteoporosis, 
foodborne illness, and commonly occurring infant diseases. The estimated present value of 
total benefit of type B disease consist of direct and indirect benefit of delaying the onset of 
the disease.  
  
Present value of lost wages from 


















Present value of lost wages 
from stroke if delayed for 5 
years 
Age year PV Age year PV 
37-44 8 $0.00 37-49 13 $0.00 
45 9 $2,430.18 50 14 $1,904.11 
46 10 $2,314.45 51 15 $1,813.43 
47 11 $2,204.24 52 16 $1,727.08 
48 12 $2,099.28 53 17 $1,644.84 
49 13 $1,999.31 54 18 $1,566.51 
50 14 $1,904.11 55 19 $1,491.92 
51 15 $1,813.43 56 20 $1,420.87 
52 16 $1,727.08 57 21 $1,353.21 
53 17 $1,644.84 58 22 $1,288.77 
54 18 $1,566.51 59 23 $1,227.40 
Total   $19,703.43 Total $15,438.15  






Est PV benefits of  delaying Type B disease = 
= PV of  Type B direct benefit + PV of Type B indirect benefit 
= ∑ (













The benefits of type B diseases are the estimated present value of medical costs 
avoided as a result of avoiding the onset of the disease through the rest of one’s lifetime 
until the average life expectancy by participating in the program. For example, if the life 
expectancy is at age 78, and the average age of onset of the disease is at age 50, then the 
present value of medical costs one could have incurred from age 50 till average lifespan is 
the benefit of avoiding the disease.  
For type B diseases, the present value of medical costs is estimated for the average 
lifespan of the individual from the onset of the disease. The direct benefit of type A diseases 
is calculated as the sum of the present value of treatment costs from average age of delayed 
age of onset through the rest of the lifetime (average age of death), discounted to 2020 
dollars. The present value of all benefits is discounted to 2020 dollars. 
 
𝑃𝑉 𝑜𝑓 𝑇𝑦𝑝𝑒 𝐴 𝑑𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 =  
= ∑ (
𝐴𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×



































Type B disease indirect benefits are the loss of productivity avoided due to avoiding 
the diseases until the age of retirement. The loss of productivity prevents the individual 
from earning wages therefore the benefits from avoiding the loss of productivity are the 
wages that would have been forgone when one is sick as a result of the disease. The indirect 
benefit of type B disease is the sum of the present values of lost wages from average age 
of onset to average age of retirement, discounted to 2020 dollars. 
Present value of Type 2 Diabetes treatment costs if avoided 
for the rest of lifetime.  
Age year PV 
37-53 18 $0.00 
54 19 $3,431.21 
55 20 $3,267.82 
56 21 $3,112.20 
57 22 $2,964.00 
58 23 $2,822.86 
59 24 $2,688.44 
60 25 $2,560.42 
61 26 $2,438.49 
62 27 $2,322.38 
63 28 $2,211.79 
64 29 $2,106.46 
65 30 $2,006.15 
66 31 $1,910.62 
67 32 $1,819.64 
68 33 $1,732.99 
69 34 $1,650.47 
70 35 $1,571.87 
71 36 $1,497.02 
72 37 $1,425.74 
73 38 $1,357.84 
74 39 $1,293.19 
75 40 $1,231.61 
76           41 $1,172.96 
77 42 $1,117.10 
78 43 $1,063.91 
Total PV   $50,777.19 






𝑃𝑉 𝑜𝑓 𝑇𝑦𝑝𝑒 𝐴 𝐼𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 =  
= ∑ (
𝐴𝑛𝑛𝑢𝑎𝑙 𝐿𝑜𝑠𝑡 𝑤𝑎𝑔𝑒𝑠 ×





















3.7 Type C Disease Benefits. 
Type C diseases and conditions are those whose cost of treatment is incurred once 
only when the child is born such as low birth weight (LBW) in infants. The direct benefit 
of Type C diseases and conditions is based on the present value of avoiding the one-time 
treatment costs of treating an infant with LBW. 
 
3.8 Cost-Benefit Analysis (CBA) Models  
Two different CBA are implemented in this study – the standard CBA model 
(Virginia methodology) which measures program benefits using self-reported dietary 
Present value of lost earnings for Type 2 Diabetes until retirement 
Age Year PV 
37-53 18 $0.00 
54 19 $252.48 
55 20 $240.46 
56 21 $229.01 
57 22 $218.10 
58 23 $207.71 
59 24 $197.82 
60 25 $188.40 
61 26 $179.43 
62 27 $170.89 
63 28 $162.75 
64 29 $155.00 









recalls and the biomarker CBA model which uses biomarkers for benefit estimation.  
Previous CBA studies on EFNEP have employed the use of the standard model (Lambur 
et al. 1998, Radhika et al. 2002., and Hradek, et al., 2017) but the use of biomarkers is quite 
uncommon in the field of nutrition education. The use of the clinically measured and 
objective biometric data will help to eliminate bias and error such as under-reporting and 
over-reporting associated with the use of self-reported data. The difference in the 
methodologies is that while the total benefit estimation of the standard Virginia method 
uses graduates practicing ONB (calculated from the self-reported behavioral data) and the 
incidence rate of the disease related to diet, the biomarker method calculates the number 
of graduates with biomarker improvement and uses the risk of disease related to the 
biomarker in estimation of the benefits.   
3.9 Standard CBA Model.  
Following the literature, I first apply the Virginia methodology utilized in prior 
CBA of EFNEP (Lambur et al. 1999, Radhika et al. 2002, & Burney et al., 2002). The 
Virginia methodology uses self-reported behavioral data to determine the participants who 
are delaying or avoiding the diseases as well as uses the incidence rate of diseases related 
to diet to quantify the total benefits of the program. To avoid or delay the onset of the 
diseases, the participants must meet the selection criteria (recommended dietary behavior 
guidelines) in Table 6 (Wessman et al., 2001). The standard methodology estimates total 
benefit as the product of the total number of graduates in the program, the incidence rate 
of the disease in low-income population, incidence rate of the disease related to diet, the 





estimated benefit of avoiding or delaying the disease. The benefits for each disease are 
calculated using the formula: 
 
𝐵𝑒𝑛𝑒𝑓𝑖𝑡 𝑓𝑜𝑟 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 = 𝑁 ×  𝐼𝑙  × 𝐼𝑑  ×  𝑔𝑟𝑎𝑑𝑂𝑁𝐵  × 𝑃𝑉(𝑏𝑒𝑛𝑒𝑓𝑖𝑡) (13) 
Where N is the total number of EFNEP graduates, Il is the incidence rate of disease in Low-
income population, Id is incidence rate of disease related to diet, gradONB is the percentage 
of graduates achieving optimal nutrition behaviors (ONB) conditions for the specific 
disease, and PV(benefit) is the present value of the estimated benefit of avoiding or 
delaying the disease. The standard model calculates the total benefit of participating in 
EFNEP as the sum of benefits for each disease. 
 
𝑇𝑜𝑡𝑎𝑙 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑚𝑜𝑑𝑒𝑙 =  ∑ 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 (14) 
3.10 Incidence Rate of the Disease/Condition 
The incidence rates which measure the probability of occurrence of the diseases in 
a low-income US population within a specified period of time are provided in Table 5. 
These were obtained from a recent CBA of Iowa EFNEP (Hradek et.al, 2017). When 
possible, incidence rates specifically for the low-income US population are utilized. Where 
rates for the low-income population cannot be found, the incidence rates for the general 
population are used. The incidence rates of the diseases related to diet measure the portion 
of the occurrence of the disease/condition believed to be related to diet over a specific 
period. The rates act as a proxy for the percentage of EFNEP graduates who would 
normally get a disease or condition, but who might avoid or delay its onset by adopting 






Table 9: Incidence Rates of Disease Related to Diet in the Low-Income Population. 
Disease/condition Incidence rate of the 
disease in the low-income 
population 
Incidence rate of the 
disease related to diet 
Colon Cancer 8.0% 80% 
Heart Disease 25.8% 50% 
Stroke 8.1% 49% 
Hypertension 29.3% 45% 
Osteoporosis 10.3% 15% 
Diabetes 28.0% 45% 
Obesity 38.0% 50% 
Foodborne Illness 16.7% 100% 
Infant Diseases 100.0% 22% 
Low Birthweight (LBW) 8.0% 100% 
Source: Hradek et.al (2017). 
 
3.11 Selecting Graduates Practicing Optimal Nutritional Behaviors (ONB) 
STATA statistical software was used to select participants among the 129 sample 
graduates who practiced optimal nutrition behaviors (ONB) at exit and those who had 
improvement in their biomarkers at exit, 6 months after graduation and 1 year after 
graduation. To be selected as practicing ONB, the participant must meet the selection 
criteria for ONB (see Table 5 in the Table 10). Graduates who were missing critical data 
related to the ONB were eliminated from the selection. The standard CBA model uses 
optimal nutritional behaviors (ONB) in Table 6 to determine whether a graduate avoids or 
delays the onset of a chronic disease or condition. The ONB criteria for a specific 
disease/condition were applied to entry and exit 24-hour food recall and the Food Practice 





practices on a scale from 1 to 5. To be considered as a graduate practicing ONB, the 
graduate must satisfy the criteria at graduation, but not at entry. This is because satisfying 
the criteria at entry implies that the participant was already practicing ONB and that 





Table 10 : Optimal Nutrition Behavior Criteria By Disease (Based on 2015-2020 DGA) 
Disease Normal Graduates 
(2000 kcal) 






Colon Cancer total fat ≤ 78gms, 
saturated fat ≤ 22gms 
fiber ≥ 25gms, 
fv ≥ 4.5cup-eq 
total fat ≤ 101, 
saturated fat ≤ 29gms 
fiber ≥ 28gms, 
fv ≥ 5cup-eq 
7&9 ≥ 4 
Heart Disease total fat ≤ 78gms, 
saturated fat ≤ 22gms 
fiber >= 25gms, 
fv>= 4.5cup-eq 
total fat ≤ 101, 
saturated fat ≤ 29gms 
fiber ≥ 28gms, 
fv ≥ 5cup-eq 
8&9 ≥ 4 
Stroke/Hypertension Fv ≥ 4.5 cup-eq, 
Ca ≥ 1000mg 
Fv ≥ 5 cup-eq, 
Ca ≥ 1000mg 
8&9 ≥ 4 
Osteoporosis Ca ≥ 1,000 mg , 
Dairy ≥ 3 cup-eq 
Ca ≥ 1,000 mg , 
Dairy ≥ 3 cup-eq 
7 ≥ 4 
Diabetes fiber ≥ 25gms, 
kcal ≤ 2300 kcal 
carbohydrate ≤ 325gms 
fiber ≥ 28gms, 
kcal ≤ 2600 kcal for 
pregnant women 
kcal ≤ 2500 kcal for 
nursing women 
carbohydrate ≥ 423gms 
7&9 ≥ 4 
Obesity fiber ≥ 25gms, 
fv ≥ 4.5cup-eq 
total fat ≤ 78gms, 
saturated fat ≤ 22 gms 
kcal ≤ 2300 kcal 
fiber ≥ 28gms, 
fv ≥ 5cup-eq 
total fat ≤ 101, 
saturated fat ≤ 29gms 
kcal ≤ 2600 kcal for 
pregnant women 
kcal ≤ 2500 kcal for 
nursing women 





Foodborne Illness - - 5&6 ≤ 2 
Infant Diseases yes for nursing - 7 ≥ 4 
Low Birthweight  yes for pregnant 
kcal>=2200 
9 ≥ 4 
The Optimal Nutrition Behavior (ONB) Criteria is based on 2015-2020 Dietary Guidelines. 
FPC # Q5. This question is about meat and dairy foods. How often do you let these foods sit out for more than two hours? 
Q6. How often do you thaw frozen foods at room temperature? 
Q7. When deciding what to feed your family, how often do you think about healthy food choices? 
Q8. How often have you prepared foods without adding salt? 
Q9. How often do you use the “Nutrition Facts” on the food label to make food choices? 





Table 11 : Percent of Graduates Practicing Optimal Nutrition Behaviors 
Disease Graduates practicing ONB 
 entry - exit 
Colon Cancer 7.5% 




Type 2 Diabetes 12.5% 
Obesity 5% 
Foodborne Illness 19.23% 
Infant Diseases 27.5% 





3.12 Biomarker CBA Model 
There are obvious limitations to self-reporting in that some people may not 
remember food intake and exercise levels correctly, or they may have difficulty quantifying 
them accurately (Combs et al., 2013). This problem may lead to underestimation or 
overestimation of the results when self-reported data are used in the analysis (Park et al., 
2018). To solve the problem of using self-reported data in the standard model, biomarkers, 
which are objective and quantitative biological measurements that indicates the potential 
for developing a disease or medical condition in an individual are used. In this model, the 
assumption is that behaviors learnt from EFNEP impact chronic disease biomarkers i.e. 
BMI, blood pressure and HbA1C. A participant’s improvement in the biomarkers provides 
a means to accurately measure the benefits of EFNEP. Biomarkers provide almost unbiased 
measurements and are therefore useful to validate self-report instruments (Hagen, 2012). 
The biomarker model also uses the PV of medical cost and lost earnings of avoiding the 
diseases (Type A, B and C) as the benefits. The difference between the two models is that 
while the standard CBA model uses graduates achieving ONB conditions for each disease 
and the incidence rate of disease related to diet, the biomarker model uses instead, the 
number of graduates improving their biomarkers and the risk of the disease related to the 
biomarker respectively. The benefit of each disease calculated using the biomarker model 
is: 
 
𝐵𝑒𝑛𝑒𝑓𝑖𝑡 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 = 𝑁 ×  𝐼𝑙  × 𝐼𝑏  ×  𝑔𝑟𝑎𝑑𝑖𝑚𝑏𝑟𝑜𝑣𝑒 𝑏𝑖𝑜  × 𝑃𝑉(𝑏𝑒𝑛𝑒𝑓𝑖𝑡) (15) 
where N is the total number of EFNEP graduates, Il is the incidence rate of disease in the 
low-income population, Ib is incidence rate of disease related to biomarker, gradimprove bio 





PV(benefit) is the present value of the estimated benefit of avoiding or delaying the 
disease. The biomarker model calculates the total benefit of participating in EFNEP as the 
sum of benefits for each disease. 
 
𝑇𝑜𝑡𝑎𝑙 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑏𝑖𝑜𝑚𝑎𝑟𝑘𝑒𝑟 𝑚𝑜𝑑𝑒𝑙 =  ∑ 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 (16) 
The risk of the disease related to the biomarkers is used as a measure of the portion of the 
occurrence of the disease/condition related to changes in the biomarker over a specific 
period. These rates give an indication of the likelihood of developing or having the 
disease/condition as a result of changes in biomarkers. 
3.13 Identification of EFNEP Graduates with Biomarker Improvement  
The goal of EFNEP is ultimately to improve the nutritional health of participants, 
therefore it follows that, by practicing these behaviors, biological characteristics such as 
weight, blood sugar, blood pressure, etc., which are indicators of good health and proper 
nutrition behaviors will be impacted. The criteria for determining graduates with biomarker 
improvement were based on general population rates of standard status categories of 
biomarkers provided by the Center for Disease Control (CDC) and the American Heart 
Association (provided in Table 12). The criteria for selecting graduates who have 
improvement in biomarkers are presented in Table 13. To be selected as having 
improvement in biomarkers at graduation, there must be quantitative change in values of 
biomarkers towards the normal category of each biomarker. For example, using the normal 
BMI range as a reference point, an overweight or obese graduate is selected to have 
improvement in BMI when BMI at graduation (exit) is less than the BMI at entry, and an 
underweight graduate is selected as having improvement in BMI when the BMI at 





graduates who had improvements in their biomarkers six months after graduation and one 
year after graduation. Graduates who were missing critical data related to biomarkers were 
eliminated from the sample. The risks of diseases associated with the biomarkers are 
presented in Table 10. Figure 2 provides the percentage of graduates who had 
improvements in their biomarkers at graduation (entry-exit), 6 months after graduation 





Table 12: Biomarker Status Categories. 
Biomarker Range (general 
population) 
Category Source  
BMI 
Less than 18.5 Underweight 
Center for Disease Control 
(2020) 
18.5 to 24.9 
Normal/Healthy 
weight range 
25.0 to 29.9 Overweight 
SBP & 
DBP  
Systolic: less than 120 
mm Hg 
 
Diastolic: less than 80 
mm Hg 
Normal 
Center for Disease Control 
(2020) 
Systolic: 120-129 mm 
Hg 
 
Diastolic: less than 80 
mm Hg 
Elevated 
Systolic: 130 mm Hg 
or higher 
 





Pulse 78 - 157 Target heart rate 
zone (50-85%) 
American Heart Association 
Guidelines for the 
prevention, detection, 
evaluation, and Management 




Below 5.7% Normal 
Center for Disease Control 
(2020) 
5.7% to 6.4% Prediabetes 




Table 13: Criteria for Selecting Graduates Who Had Biomarker Improvement 
Biomarker Direction of Improvement Criteria for determining improvement in 
biomarkers at graduation 
BMI 
Underweight to Normal 
entry BMI is less than 18.5 &  
exit BMI greater than entry BMI &  
exit BMI < 24.9 
Overweight and Obese to 
normal 
entry BMI > 24.9 & 





 exit BMI >18.5 
SBP Elevated and high BP to 
normal 
entry SBP > 129 & 
exit SBP < entry SBP 
DBP 
High BP to Normal 
entry DBP > 80 & 
exit DBP < entry DBP 
Pulse 
Changes towards the target 
heart rate zone 
entry Pulse < 78 & 
exit Pulse > entry Pulse & 
exit Pulse < 132 
HbA1C Changes from prediabetic 
and diabetic towards 
normal 
entry HbA1C > 5.7 & 
exit HbA1C < entry HbA1C 
 
 
Table 14: Risk of Chronic Disease Associated with Changes in Biomarkers 




Type A Diseases  
Heart Disease BMI 21% WHO, 2009 
Hypertension Blood pressure 12% Harvard SPH, 2020 
Colorectal Cancer BMI 30% Harvard SPH, 2020 
Stroke Pulse 23% WHO, 2009 
 
Type B Diseases  
Type 2 diabetes HbA1C 66% Harvard SPH, 2020 
Obesity BMI 100% Harvard SPH, 2020 
Osteoporosis1  48% Hradek et.al (2017). 
Foodborne illness1  100% Hradek et.al (2017). 
 
Type C diseases  
Infant diseases1  22% Hradek et.al (2017). 
1. There was no direct relationship between biomarkers and osteoporosis, foodborne illness and infant 








Figure 2: Percentage of graduates having improvement in biomarker 
BMI and pulse rate had the highest percentage of graduates improving their biomarkers for 
all the three periods. There was an improvement in the percentage of graduates who had 
improved BMI, but there was not much change from 6 month to 1 year post-EFNEP . SBP 
had the lowest percent of graduate improving at all time periods (15.4%, 11.5%, 13.5%). 
DBP had the highest percentage of improvement at 1 year after graduation. The percentage 
of graduates improving in their blood sugar (HbA1C) was highest at exit (30.8%) and 
lowest after one year of graduation (17.3%).  There were lower percent of graduates with 
improvement for pulse at 1 year after graduation (44.2%) compared to the higher percent 










The final sample size used in the analysis is 129 EFNEP graduates with complete 
data. Table 11 below provides the number and percentages of graduates who practiced 
ONB at exit of the program, as well as graduates who improved their biomarkers for the 
diseases at exit, 6 months post and one year post. For all the diseases except foodborne 
illness and infant diseases, the percentage of graduates with improved biomarkers exceeded 
the percentage with improved ONB across all three periods: graduation, six months after 
graduation and one year after graduation. No graduates were selected for practicing ONB 
or improving biomarkers for low-birth-weight disease. This is because there were no 
pregnant participants in the study sample. The highest percentage of graduates practicing 
ONB at exit is 27.5% for avoiding infant diseases and the lowest percentage of graduates 
practicing ONB at exit is 5% for avoiding obesity. The highest percentage of graduates 
improving their biomarkers are 51.92% for avoiding stroke at exit, 53.85% for avoiding 
stroke at 6 months after graduation and 50% for avoiding colon cancer, heart disease, and 
obesity after one year of graduation.  
Table 15: Percentage of Graduates Improving in Their Biomarkers for Each Disease 
Disease 
Number & percentage of graduates avoiding disease 
Graduates practicing 
ONB 
Graduates improving in biomarkers 
entry - exit entry-exit entry-6months entry-1yr 
Colon Cancer  7.5%  42.31%  50.0%  50.0% 
Heart Disease  7.5%   42.31%   50.0%   50.0%  
Stroke  12.5%   51.92%   53.85%  44.23%  
Hypertension  12.5%   30.77%   25.00%  132.69%   





Type 2 Diabetes  12.5%   30.77%   19.23%  17.31%  
Obesity  5%  42.31%  50.0%  50.0%   
Foodborne Illness  19.23%   19.23%   19.23%   19.23%   
Infant Diseases  27.5%   9.62%   9.62%  9.62%  
Low Birth Weight - - - - 
 
A summary of the CBA results calculated using the cost-benefit ratio formula in 
equation (1) for both models is provided in Table 12. The PV of total benefit is derived by 
the summation of the total direct benefit and the total indirect benefit which is then 
compared to the total costs. The total cost of the program ($1,822,135.82) was obtained by 
adding the total administrative costs from the Washington and Colorado EFNEP programs. 
The cost-benefit ratio is derived by dividing the total benefit by the total cost. From 
Table 12, the estimated PV of total direct benefits, which are the medical costs avoided or 
delayed, obtained by using the biomarkers at graduation ($15,695,056.81), six months after 
graduation ($15,610,152.67), and one year after graduation ($15,150,042.08) are higher 
than the estimated PV of total direct benefit ($4,383,751.24) obtained at graduation when 
dietary recalls (self-reported data) are used.  
The PV of total indirect benefits (lost productivity/wages avoided or delayed) 
obtained using the biomarkers at graduation ($1,375,117.55), six months after graduation 
($1,444,849.32), and one year after graduation ($1,420,879.22) is much higher than the 
estimates of PV of total indirect benefits obtained at graduation from using the self-reported 
data ($361,939.46). The estimated PVs of direct, indirect and total benefits  calculated from 
the standard model, using self-reported data, are lower than the estimated PVs of direct, 
indirect and total benefits calculated using the biomarker model. The PV of total benefits 





of $17,070,174.36, $17,055,002.00, and $16,570,921.30 for all the three time periods using 
the biomarker model. Benefits were compared to the costs and incorporated into a benefit-
cost ratio. From the standard model, EFNEP generates a benefit-cost ratio of $2.60: $1.00. 
The biomarker model yields benefit-cost ratios of $9.37: $1.00, $9.36: $1.00, and $9.09: 
$1.00 at exit, six months post and 1 year post respectively.  
Table 16: Cost-Benefit Analysis Results 
 Standard model Biomarker model 
entry - exit entry - exit entry - 6 month entry – 1 year 
Total direct benefits $4,383,751.24 $15,695,056.81 $15,610,152.67 $15,150,042.08 
Total indirect benefits $361,939.46 $1,375,117.55 $1,444,849.32 $1,420,879.22 
Total benefits $4,745,690.69 $17,070,174.36 $17,055,002.00 $16,570,921.30 
Total costs $1,822,135.82 $1,822,135.82 $1,822,135.82 $1,822,135.82 
Cost-benefit ratio $2.60: $1.00 $9.37: $1.00 $9.36: $1.00 $9.09: $1.00 
 
4.2 Sensitivity Analysis 
Healthcare evaluations are prone to the uncertainties that beset the methodologies, 
assumptions and data which have implications on the interval of the estimates (Briggs and 
Gray, 1999). Sensitivity analysis is therefore important to evaluate the robustness of the 
assumptions in CBA. This is to determine how the uncertainties in the models and the data 
impact the estimated CBA results, and hence determine the range or confidence of the 
estimates (Sendi, Garfni and Birch, 2002).   
The 5% discount rate, which describes the level of uncertainty in the time value of 
money, is commonly used in health- related studies (Attema et al., 2018). Since there is 
some uncertainty about using this value, a sensitivity analysis is done by varying the 
discount rate (0%, 3%, 7% and 10%).  The incidence rates of the infant disease and 





studies found in the literature that provided an association of biomarkers to those diseases, 
so it is important to conduct a sensitivity analysis on these rates in the biomarker model. A 
sensitivity analysis is performed by reducing the incidence rates of infant disease and 
foodborne illness used in the biomarker model by 50%.  







Entry – Exit Entry – Exit 
Entry - 
6months 
Entry – 1year  
0% discount rate $6.57 $24.54 $22.65 $21.99 
($6.57 - 
$22.65) 
3% discount rate $3.60 $13.22 $12.83 $12.47 
($3.60 - 
$13.22) 
7% discount rate $1.98 $6.94 $7.10 $6.89 
($1.98 - 
$7.10) 
10% discount rate $1.42 $4.71 $4.95 $4.80 
($1.42 - 
$4.95) 
50% reduction of 
incidence rates of infant 
diseases and foodborne 
illness 














The results indicate that the CBA outcome remained positive after altering the 
parameters. However, the benefit-cost ratio changed significantly for each analysis. The 
findings from the sensitivity analysis are consistent with that of the primary results of the 
cost-benefit analysis. The results were more sensitive to the varying the discount rate than 
to reducing the incidence rates for foodborne and infant diseases. Assuming no uncertainty 
in the model (0% discount rate) had the greatest impact on the benefit-cost ratios for both 
models. The cost-benefit ratio of the biomarker model lies within the sensitivity interval of 
$4.71 - $24.54: $1.00 for all the three time periods. The cost-benefit ratio of the standard 





leads to the same conclusion that estimates from the biomarker model are higher than 






5.1 Discussion and Recommendation 
The cost-benefit ratios presented in Table 12 indicate that EFNEP generates 
significant return on investment. These results corroborate the positive returns found in 
prior EFNEP studies (Rajgopal et al., 2002; Lambur et al., 2009 and Hradek et al., 2017).  
The standard model, which uses self-reported dietary recall data from EFNEP participants, 
indicates a $2.67 return on every $1.00 invested (sensitivity: $1.42 - $6.57). The result 
from the standard model possesses measurement errors due to the use of self-reported 
dietary recalls. Therefore, to address the problems associated with the use of self-reported 
data, objective and clinically measured biomarkers of participants collected at graduation, 
6 months after graduation and 1 year after graduation are used to estimate the benefits of 
EFNEP.  
The results from using the biomarkers indicate an average return of $9.27 on every 
$1.00 invested (sensitivity: $4.71 - $24.54). The significant difference in the results from 
the two models emphasizes the bias, measurement errors, and underestimation associated 
with the use of self-report data (Rosenman et al., 2011). The use of biomarkers for chronic 
disease risk provides more accurate results that better reflect the true benefit of EFNEP. 
The results from both models indicate that taxpayer dollars are used effectively in 
addressing the issue of nutrition insecurity among low-income families. As individuals 
learn and implement proper nutritional behaviors and can avoid or delay the onset of these 
diseases by participating in the program, they are able to save these medical costs which 
may be used in purchasing food and other necessities for their families. The benefit-cost 





period which suggests that the nutritional behaviors derived from the EFNEP program are 
maintained for at least 1 year after participants graduate from the program.  
Results from this study suggest that the program provides an effective use of 
taxpayer dollars in addressing nutrition insecurity. EFNEP participants experience 
sustained improvement in nutritional health through the adoption and maintenance of the 
behaviors taught in the program, and in wellbeing by avoiding or delaying specific 
disease/conditions. The results off this study can be used by EFNEP coordinators to 
demonstrate to policymakers the positive value of the program as well as leverage the 
information to increase the amount of funding available in support of this program obtained 
from a limited pool of state and federal dollars. Consequently, additional funding to be 
allocated to the program will allow to increase the impact of nutrition education 
disseminated to low-income families and youth in the 50 states, the U.S. territories, and the 
District of Columbia.  
The results of this study show how using biomarkers could provide more accurate 
estimates of the true benefits of EFNEP. Nonetheless, this is a preliminary study with a 
small sample size. Therefore, additional studies will be needed using a large nationally 
representative dataset to ascertain and make firm generalizations of the results from this 
study. To effectively evaluate the benefits of EFNEP, we suggest that self-reported dietary 
recalls should be supplemented with biological markers (biomarkers) which are objective 
and reflective of nutritional intake to estimate the benefits of the program. Considering the 
additional cost of collecting these biomarkers from EFNEP participants, we recommend 





EFNEP coordinators. For example, biometric data from EFNEP participants could be 
collected once every 5 years to determine whether EFNEP remain worthwhile. 
5.2 Limitations of study 
A key limitation of this study is the large share of participants with missing data on 
dietary recalls and biomarkers. About 50% of the total sample had to be dropped due to 
incomplete data.  Because I compare graduates practicing ONB to those improving in 
biomarkers, I ensured that observations in the data had complete values for both dietary 
recalls, biomarkers, and food practice scores, but this led to a significant reduction in the 
sample size. Other data issues were the unavailability of more representative data on the 
incidence rates of disease related to biomarkers and the data on the costs of collecting 
biometric data from participants.  Since EFNEP participants are low-income earners and 
are mostly women, rates of diseases related to biomarkers for low-income earners or 
women would have provided more accurate and representative results than using general 
population rates. Also, to determine the direct costs of collecting the biometric data from 
participants, it will require additional cash incentives for the volunteers, the cost of labor 
for collecting the data and the cost of medical supplies such as scale, stadiometer, blood 
pressure machine, blood sugar test kits, etc.  
An important factor to consider, in assessing the impacts on graduates who 
benefited from the program at graduation, are the individuals’ underlying medical 
conditions. This information could have been inferred from the data with the observations 
that were potential outliers. Nonetheless it will be difficult to determine if participants had 
underlying medical conditions, such as stroke, cancer, etc. Knowing this information could 





The percentage of EFNEP graduates improving each biomarker were estimated as the as 
the percentage of EFNEP graduates who had quantitative improvement in biomarkers (e.g. 
an obese participant having a reduction in BMI at exit) regardless of the magnitude of 
improvement. Another approach is to consider participants who made qualitative 
improvement, or those who had categorical movement e.g., obese to normal weight. Both 
approaches have their own limitations. Regardless of the magnitude of the difference in 
biomarker values at entry and exit, moderate improvement is clinically significant as an 
improvement in health (Kirk et al., 2005 and Lemstra et al., 2016). Categorical changes of 
these biomarkers will require a longer duration outside that of the program to occur, 
therefore, this is expected to occur when these behaviors are maintained long-term. 
The biometric data for blood sugar (HbA1C) were collected one time for each 
participant. Even though this is objective and more accurate than self-reported data, this 
could have potential measurement errors since the level of blood sugar can be highly 
influenced by other factors, such as the kind of food taken in a particular day, the day’s 
activity, etc. A more accurate measure of blood sugar levels could have been the weighted 
average of multiple measures collected. 
5.3 Future Research 
Biomarkers, which are indicators of nutrient intake, status, or functional effects are 
needed to support evidence-based clinical guidance and effective health programs and 
policies related to food, nutrition, and health (McClure 2002). Studies by Pico et al. ( 2019), 
and McClure (2002) and others have established the impact of nutritional behavior on the 
biomarkers of individuals. Since diet behavior impacts biomarkers, it will be useful to 





biomarkers. Such a model could be used to estimate or predict biometric changes of EFNEP 
participants given their dietary recalls so that, costs incurred in collecting biometric data 
from participants to evaluate EFNEP in the future could be avoided in the future. For more 
accurate results, this would need to be done using biometric and dietary recall data from a 
large, nationally representative sample of EFNEP participants. 
Another important question to ask about the impact of EFNEP is how the behaviors 
learnt from the program impact the biomarkers of participants. Since it was assumed in the 
biomarker model that EFNEP impacts biomarkers, it is important to determine if the 
changes in the biomarkers at graduation, 6 months and 1 year after graduation were caused 
by EFNEP or if these changes occurred randomly. Statistical tests, such as paired sample 
tests and ANOVA, will be important in determining the statistical significance of the effect 
of the program on these biomarkers. The results from this study will provide another means 
of evaluating the programs impact and further guide EFNEP program coordinators 
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